Nonsurgical breast cancer treatment

About 25% of newly diagnosed breast cancer is ductal carcinoma in situ (DCIS) and it is usually treated with surgery and sometimes radiation. However, only about half of the incidences of DCIS are likely to spread, leading many to seek a less invasive treatment. Scientific American recently highlighted work conducted at Harvard University using RNA that was designed to turn off the HoxA1 gene known to be involved in breast cancer development. The research was conducted in mice and involved injecting the RNA nanoparticles into the nipples of the mice. This intraductal therapy was successful at reducing the malignant cancer incidence from 100% to 25%. For more information on treating early stage breast cancer without surgery, see our page on breast cancer prevention.

Tell us what you think

This form does not collect your email address. If you would like us to respond, please send questions to
This field is for validation purposes and should be left unchanged.
We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today